证券代码：301211 证券简称：亨迪药业 公告编号：2023-051 湖北亨迪药业股份有限公司 关于变更签字注册会计师的公告 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 湖北亨迪药业股份有限公司（以下简称"公司"）于 2023 年 4 月 24 日召开第一届董事会第十七次会议、第一届监事会第十一次会 议，并于 2023 年 5 月 19 日召开了 2022 年年度股东大会，审议通过 了《关于续聘公司 2023 年度审计机构的议案》，续聘大信会计师事 务所（特殊普通合伙）（以下简称"大信会计师事务所"）为公司 2023 年度的审计机构。具体内容详见公司 2023 年 4 月 25 日、2023 年 5 月 19 日披露于巨潮资讯网（http://www.cninfo.com.cn）的相 关公告。 公司于近日收到大信会计师事务所出具的《关于变更 2023 年度 审计签字注册会计师的告知函》，现将具体情况公告如下： 潘杨州先生，拥有注册会计师，具有证券业务服务经验，2014 年取得注册会计师职业资格，从 2012 年至今在大信会计师事务所（特 殊普通合伙）从 ...

Financial Performance - The net profit for the third quarter of 2023 reached CNY 144,514,979.02, a significant increase of 83.83% compared to CNY 78,551,187.11 in the same period last year[3] - The company reported an operating profit of CNY 171,168,058.78, which is a 83% increase from CNY 93,606,855.47 in the previous year[3] - Operating revenue increased by 56.93% to CNY 542,445,746.24 from CNY 345,656,815.72 in the same period last year[31] - Total operating revenue for the third quarter reached ¥542,445,746.24, a significant increase from ¥345,656,815.72 in the same period last year, representing a growth of approximately 56.9%[43] - Basic and diluted earnings per share for the quarter were both ¥0.50, compared to ¥0.27 in the previous year, reflecting an increase of approximately 85.2%[39] - The net profit attributable to shareholders for the current period is CNY 31,476,110.61, reflecting a 30.32% increase year-over-year[48] - The net profit attributable to shareholders after deducting non-recurring gains and losses is CNY 30,899,063.90, which is a 45.57% increase compared to the previous year[48] Assets and Equity - The total assets as of September 30, 2023, amounted to CNY 2,498,883,170.39, slightly up from CNY 2,497,721,443.51 at the beginning of the year[1] - The company's total equity attributable to shareholders increased to CNY 2,326,723,462.93 from CNY 2,276,499,452.63, reflecting a growth of 2.2%[1] - Non-current assets totaled CNY 379,696,150.53, while total assets reached CNY 2,498,883,170.39, compared to CNY 270,826,069.16 and CNY 2,497,721,443.51 respectively in the previous year[19] - The total assets at the end of the reporting period amount to CNY 2,498,883,170.39, a slight increase of 0.05% from the end of the previous year[48] - The equity attributable to shareholders at the end of the reporting period is CNY 2,326,723,462.93, which is a 2.21% increase from the previous year[48] Cash Flow - Cash and cash equivalents at the end of the third quarter were CNY 1,729,396,597.93, down from CNY 1,858,088,871.05 at the beginning of the year, indicating a decrease of 6.9%[5] - Cash flow from operating activities decreased by 32.99% to CNY 82,988,321.06, primarily due to significant pre-receipts in December 2022[31] - The net cash flow from operating activities for the year-to-date is CNY 82,988,321.06, showing a decrease of 32.99% compared to the same period last year[48] - The cash inflow from investment activities for the current period is CNY 377,510.89, compared to CNY 63,000.00 in the previous period[48] Expenses - R&D expenses surged by 131.24% to CNY 34,932,093.15, driven by the company's integrated strategy of "raw materials + formulations" and progress in consistency evaluation[31] - Total operating costs amounted to ¥374,327,664.34, up from ¥261,859,834.81, indicating an increase of about 42.7% year-over-year[43] - Tax expenses for the quarter were ¥4,467,473.08, up from ¥2,280,330.08, representing an increase of approximately 96.2% year-over-year[43] - Sales expenses increased to ¥17,471,902.46 from ¥13,790,374.69, reflecting a rise of about 26.5%[43] - Management expenses decreased slightly to ¥35,340,769.90 from ¥37,409,148.74, showing a reduction of approximately 5.5%[43] Shareholder Information - The company’s total number of common shareholders at the end of the reporting period was 24,588[33] - The largest shareholder, Shanghai Yongda Sheng Business Consulting Co., Ltd., holds a 38.25% stake, amounting to 110,160,000 shares[33] Liabilities - The total liabilities amounted to CNY 172,159,707.46, compared to CNY 221,221,990.88 in the previous year[19] - Contract liabilities decreased by 81.79% to CNY 12,692,792.18 from CNY 69,720,405.61 in the previous year[31] Audit Status - The company has not undergone an audit for the third quarter report[24]

具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023 年第三季度报告》（公告编号：2023-048）。 证券代码：301211 证券简称：亨迪药业 公告编号：2023-050 湖北亨迪药业股份有限公司 第二届监事会第三次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届监事会第三次会议 于 2023 年 10 月 13 日以电话及邮件方式送达至全体监事，本会议于 2023 年 10 月 17 日以现场方式召开。本次会议应参会监事 3 人，实际参会监事 3 人。会议 由监事会主席全俊先生召集并主持。本次会议的召集、召开和表决程序符合《中 华人民共和国公司法》和《公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 会议审议并通过了如下议案： 1、《2023 年第三季度报告》 表决结果：3 票同意、0 票反对、0 票弃权。该项议案获审议通过。 2、关于对 2023 年第三季度报告的审核意见的议案 经审议，监事会认为董事会编制和审核的公 ...

本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 证券代码：301211 证券简称：亨迪药业 公告编号：2023-049 湖北亨迪药业股份有限公司 第二届董事会第三次会议决议公告 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第三次会议 于 2023 年 10 月 13 日以电话及邮件方式送达至全体董事，会议于 2023 年 10 月 17 日以现场和通讯方式召开。本次会议应参会董事 8 人，实际参会董事 8 人， 其中现场出席会议的董事 3 人，董事黄雪强、朱晓兵，独立董事项光亚、傅仁辉、 姚克以通讯方式参加会议。会议由公司董事长程志刚主持，公司监事和高级管理 人员列席会议。本次董事会会议的召集、召开和表决程序符合《中华人民共和国 公司法》等法律法规和《公司章程》的有关规定，会议合法、有效。 二、董事会会议审议情况 会议审议并通过了如下议案： 1、《2023 年第三季度报告》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023 年第三季度报告》。（公告编号：2023-048） 表决结果：赞 ...

Financial Performance - The company's operating revenue for the reporting period reached ¥405,758,580.58, representing a 68.80% increase compared to the previous year[2]. - Net profit attributable to shareholders was ¥113,038,868.41, marking a 107.80% increase year-over-year[2]. - The basic earnings per share increased to ¥0.39, up 105.26% from the previous year's ¥0.23[2]. - The total assets at the end of the reporting period were ¥2,492,507,929.66, showing a slight decrease of 0.21% from the previous year[2]. - The net assets attributable to shareholders increased to ¥2,294,547,429.95, reflecting a 0.79% growth compared to the previous year[2]. - The net cash flow from operating activities was ¥47,336,095.03, which is a decrease of 48.80% from the previous year[2]. - The company's revenue for the reporting period reached ¥405,758,580.58, a year-on-year increase of 68.80%, primarily due to increased domestic sales of raw materials and related formulations[38]. - The cost of sales amounted to ¥245,874,842.46, reflecting a year-on-year increase of 43.70%, attributed to the same factors driving revenue growth[38]. - Research and development expenses surged by 110.62% to ¥20,214,826.43, as the company actively advanced its "raw materials + formulations" integration strategy[38]. - The company reported a significant increase in sales expenses, which rose by 44.87% to ¥13,372,479.14, driven by intensified marketing efforts[38]. Industry and Market Position - The company operates in the pharmaceutical manufacturing industry, focusing on chemical drug raw materials and formulations[11]. - The company focuses on the research, production, and sales of chemical raw materials (including intermediates) and formulations, and offers contract development and manufacturing services (CDMO) based on customer needs[13]. - The company has achieved significant recognition, being a qualified global supplier for major pharmaceutical companies such as Sanofi, GlaxoSmithKline, and Abbott, with products registered in over 80 countries[17]. - The company is recognized as a high-tech enterprise in Hubei Province, continuously investing in new technologies, processes, and product development[17]. - The company is committed to high-quality development in the pharmaceutical manufacturing sector, supported by national policies aimed at enhancing drug supply security and innovation[12]. Product Development and Innovation - The company emphasizes the development of children's medications and rare disease drugs, aligning with national policies to encourage innovation in these areas[12]. - The company is advancing the research and development of new formulations, including sustained-release capsules and enteric-coated capsules[29]. - The company is focusing on innovative production processes to reduce costs and improve efficiency, thereby enhancing its competitive edge[32]. - The company has developed a series of Ibuprofen derivative products to meet diverse customer needs and expand market reach[29]. - The company has successfully passed the FDA certification and is registered in multiple countries including the US and EU[22]. Environmental Compliance and Safety - The company has a wastewater treatment capacity of 3,000 tons per day, ensuring compliance with discharge standards of COD ≤ 657 mg/L and ammonia nitrogen ≤ 114 mg/L[128][130]. - The company has established a centralized exhaust gas treatment facility with a capacity of 260,000 cubic meters per hour, adhering to the GB37823-2019 emission standards[131]. - The company has committed to environmental compliance, with all wastewater and waste gas emissions meeting regulatory standards[126][128]. - The company has implemented various technologies for waste gas treatment, including membrane absorption and carbon fiber adsorption, to recover harmful substances[132][133]. - The company has established a comprehensive safety production management system and conducted regular safety training and emergency drills[148]. Shareholder Engagement and Governance - The company reported a significant increase in revenue, achieving a total of 146.7 million shares voted in favor of key proposals during the shareholder meetings, representing 99.9991% approval[78]. - The company has maintained a high level of shareholder engagement, with 61.19% participation in the second temporary shareholder meeting[82]. - The company is committed to transparency, as evidenced by the unanimous approval of the 2022 annual report and profit distribution plan during the annual shareholder meeting[89]. - The company successfully passed the 2022 annual financial settlement report with unanimous support from shareholders, indicating strong confidence in financial management[89]. - The company approved the 2022 annual internal control self-assessment report with 100% of the voting shares in favor[94]. Future Plans and Investments - The company plans to use CNY 6,000 million of the raised funds for permanent working capital supplementation, completed by November 2022[56]. - The company has committed to invest CNY 15,500 million in the high-end pharmaceutical formulation internationalization project, expected to be completed by December 2024[53]. - The annual production capacity of the ibuprofen raw material project is set at 5,000 tons, with the expected completion date adjusted to June 2025 due to global economic and market conditions[52]. - Hendi Pharmaceutical plans to enter two new regional markets, aiming to increase its market share by 10% in these areas[200]. - The company is investing RMB 50 million in R&D for new drug formulations and innovative technologies in the upcoming fiscal year[200].

证券代码：301211 证券简称：亨迪药业 公告编号：2023-046 湖北亨迪药业股份有限公司 第二届监事会第二次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届监事会第二次会议 于 2023 年 8 月 11 日以电话及邮件方式送达至全体监事，本会议于 2023 年 8 月 24 日以现场方式召开。本次会议应参会监事 3 人，实际参会监事 3 人。会议由 监事会主席全俊先生召集并主持。本次会议的召集、召开和表决程序符合《中华 人民共和国公司法》和《公司章程》的有关规定，会议合法、有效。 二、监事会会议审议情况 会议审议并通过了如下议案： 1、《2023 年半年度报告全文及其摘要》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023 年半年度报告》（公告编号：2023-043）及《2023 年半年度报告摘要》（公告 编号：2023-044）。 表决结果：3 票同意、0 票反对、0 票弃权。 该项议案获审议通过。 2、《关于对 2023 ...

国泰君安证券股份有限公司 关于湖北亨迪药业股份有限公司 2023 年半年度持续督导跟踪报告 保荐机构名称：国泰君安证券股份有限公司 被保荐公司简称：亨迪药业 保荐代表人姓名：李懿 联系电话：021-38676515 保荐代表人姓名：王栋 联系电话：021-38677593 一、保荐工作概述 | 项目 | 工作内容 | | --- | --- | | 1、公司信息披露审阅情况 | - | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次数 | 0 次 | | 2、督导公司建立健全并有效执行规章制度的 情况 | - | | （1）是否督导公司建立健全规章制度（包括 但不限于防止关联方占用公司资源的制度、 募集资金管理制度、内控制度、内部审计制 | 是 | | 度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3、募集资金监督情况 | - | | （1）查询公司募集资金专户次数 | 次 6 | | （2）公司募集资金项目进展是否与信息披露 文件一致 | 是 | | 4、公司治理督导情况 | - | | （1）列席公司股东大会次数 | 未列 ...

证券代码：301211 证券简称：亨迪药业 公告编号：2023-045 湖北亨迪药业股份有限公司 第二届董事会第二次会议决议公告 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《2023 年半年度报告》（公告编号：2023-043）及《2023 年半年度报告摘要》（公告 编号：2023-044）。 表决结果：赞成 8 票，反对 0 票，弃权 0 票。该项议案获审议通过。 2、《2023 年半年度募集资金存放与使用情况的专项报告》 经审议，董事会认为：公司严格按照《证券法》及《深圳证券交易所创业板 股票上市规则》等规定，并根据自身实际情况，完成了《2023 年半年度募集资 金存放与使用情况的专项报告》的编制工作。2023 年半年度募集资金的存放和 本公司及董事会全体成员保证公告内容真实、准确、完整，不存 在任何虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 湖北亨迪药业股份有限公司（以下简称"公司"）第二届董事会第二次会议 于 2023 年 8 月 11 日以电话及邮件方式送达至全体董事，本次会议于 2023 年 8 月 24 日以现场和通讯方式召开。本次会议应参会董事 ...

根据《上市公司监管指引第2号――上市公司募集资金管理和使用的监管要求》《深圳证 券交易所上市公司自律监管指引第2号――创业板上市公司规范运作》以及《深圳证券交易所 创业板上市公司自律监管指南第2号――公告格式》的相关规定，湖北亨迪药业股份有限公司 （以下简称"公司"）将2023年半年度募集资金存放和使用情况报告如下： 一、募集资金基本情况 （一）扣除发行费用后的实际募集资金金额、资金到账时间 根据中国证券监督管理委员会"证监许可[2021]3639 号"文《关于同意湖北亨迪业股份 有限公司首次公开发行股票注册的批复》，本公司通过向社会公开发行人民币普通股（A 股） 6,000 万股，发行价 25.80 元，募集资金总额 1,548,000,000.00 元。扣除发行费用后募集资 金净额为人民币 1,400,732,340.85 元。募集资金已于 2021 年 12 月 16 日划至公司指定账户。 大信会计师事务所（特殊普通合伙）于 2021 年 12 月 16 日对公司首次公开发行股票的资金到 位情况进行了审验，并出具了大信验字[2021]第 2-10059 号《验资报告》。 （二）募集资金使用情况 截至 2 ...

2023 年半年度非经营性资金占用及其他关联资金往来情况汇总表 法定代表人：程志刚 主管会计工作负责人： 易廷浩 会计机构负责人：全纯华 编制单位：湖北亨迪药业股份有限公司 单位：人民币万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司 | 2023 年期 初占用资 | 2023 年半年度 占用累计发生 | 2023 年半 年度占用 资金的利 | 2023 年半 年度偿还 | 2023 年半年 度期末占用 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 核算的会计科目 | 金余额 | 金额 （不含利息） | 息 （如有） | 累计发生 金额 | 资金余额 | 原因 | | | 现大股东及其附属 | | | | | | | | | | | | 企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 总 计 | | | | | | | | | | | | 其它关联资金往来 | 资金往 ...